- Home
- BNS vs BMY Comparison
BNS vs BMY Comparison
Compare BNS & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNS | BMY |
|---|---|---|
| Founded | 1832 | 1887 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.0B | 113.5B |
| IPO Year | 2025 | 2006 |
Fundamental Metrics
Financial Performance| Metric | BNS | BMY |
|---|---|---|
| Price | $92.23 | $61.50 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 15 |
| Target Price | ★ $106.00 | $61.73 |
| AVG Volume (30 Days) | 1.4M | ★ 7.6M |
| Earning Date | 05-27-2026 | 04-30-2026 |
| Dividend Yield | 4.21% | ★ 4.38% |
| EPS Growth | N/A | ★ 178.46 |
| EPS | N/A | ★ 2.93 |
| Revenue | N/A | ★ $48,194,000,000.00 |
| Revenue This Year | $26.54 | N/A |
| Revenue Next Year | $4.77 | N/A |
| P/E Ratio | ★ $18.76 | $20.87 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $62.98 | $42.52 |
| 52 Week High | $95.74 | $68.64 |
Technical Indicators
Market Signals| Indicator | BNS | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 33.67 |
| Support Level | $85.88 | $56.46 |
| Resistance Level | $95.15 | $62.39 |
| Average True Range (ATR) | 1.38 | 1.11 |
| MACD | -0.25 | -0.50 |
| Stochastic Oscillator | 19.30 | 4.89 |
Price Performance
Historical ComparisonAbout BNS Bank Nova Scotia Halifax Pfd 3
Bank of Nova Scotia is a global financial-services provider with over CAD 1.5 trillion in assets as of the end of April 2026. It has four major business segments: Canadian banking, international banking, global wealth management, and global banking and markets. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Latin America.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.